Molecular Epidemiology of Therapy-related Acute Myeloid Leukemia/Myelodysplastic Syndrome (AML/MDS)

Status unconfirmed

Conditions studied: Leukemia, Myelodysplastic Syndrome

In brief

The goal of this research study is to identify biologic and lifestyle factors that may increase a person's risk of developing acute myeloid leukemia or myelodysplastic syndrome after treatment for a previous cancer (treatment-related AML/MDS).

Key facts

Study ID

NCT00525746

Run by

M.D. Anderson Cancer Center

People needed

191

Starts

2006-03-31

Expected to finish

2025-03-31

Last updated by the study team

2020-01-14

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Age 18 years or older
• Willing and able to provide written informed consent and authorization
• Willing to donate a saliva sample or 10 ml of blood and to complete a self-administered or personal interview
• A histologically confirmed diagnosis of AML or MDS (cases only)
• A history of a previous primary malignancy that was treated with chemotherapy and/or radiation therapy (cases only)
• Enrolled in leukemia/MDS studies under protocol ID00-173 or ID03-0250 (cases only)
• Treated for a primary malignancy at MDACC (controls only)
• Matched to cases (2:1) by cases' prior malignancy(site, treatment (chemo and/or radiation), year of diagnosis (+/- 3 years)), age (+/- 5 years), sex, and ethnicity. (controls only)

You may not qualify if…

• Under 18 years of age
• History of second primary malignancy (controls only)

Where it is running

• University of Texas MD Anderson Cancer Center — Houston, Texas, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.